Biovica International AB logo

BIOVIC B - Biovica International AB News Story

SEK42 -0.5  -1.2%

Last Trade - 12/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £102.7m
Enterprise Value £89.6m
Revenue £150k
Position in Universe 896th / 1831

BRIEF-Biovica Initiates Collaboration With Mayo Clinic To Study DiviTum

Wed 8th April, 2020 7:11am
April 8 (Reuters) - Biovica International AB  BIOVICb.ST :
    * BIOVICA INITIATES A COLLABORATION WITH MAYO CLINIC TO
STUDY
DIVITUM ®  FOR THE ON-TREATMENT MONITORING OF METASTATIC BREAST
CANCER PATIENTS RECEIVING CDK 4/6 INHIBITORS
    * BIOVICA AND MAYO CLINIC HAVE ENTERED INTO AN AGREEMENT TO
STUDY
CLINICAL BENEFIT OF USING DIVITUM(®)

Source text for Eikon:  ID:nWkrGTrsg 
Further company coverage:  BIOVICb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.